ABSTRACT
PURPOSE: The aperture shape controller (ASC) is a tool on a radiation therapy planning system to reduce complexity by increasing the aperture size of multileaf collimator (MLC). The purposes of this study were to clarify the effect of the dose index on the treatment plan when the intensity of ASC is changed and then to clarify the effect on the verification result in the individual patient-specific quality assurance (QA) using the verification phantom. METHODS: For four types of mock structures presented at AAPM TG-119, volumetric modulated arc therapy (VMAT) treatment plans with three dose levels were set without using the ASC for each of these four types. ASC settings were changed to very low, low, moderate, high and very high for the treatment plan, and the treatment plan was recreated without changing the planning target volume (PTV) and/or OAR dose constraints. The dose index of the treatment plan was then evaluated. The plan was also transferred by the true composite method to the assessment phantom, and patient-specific QA was evaluated. RESULTS: The frequency of dose constraint deviation by changing the ASC was 3.6% (2/55). In patient-specific QA, when the ASC setting was set to moderate, the γ analysis passing rate increased by 1.5% compared to the case without the ASC. In the treatment plan with a γ analysis pass rate of 95% or less without ASC, a 2.7% increase in the γ analysis pass rate was observed by setting the ASC to moderate. CONCLUSION: We found that setting the ASC tended to improve patient-specific QA. Compared to when the ASC was not set, the evaluation result of patient-specific QA was improved without violating the dose constraints of the PTV and/or organ at risk (OAR). In particular, the improvement was notable for the case where the evaluation result of patient-specific QA was 95% or less when the ASC was not used.
Subject(s)
Radiotherapy Planning, Computer-Assisted , Radiotherapy, Intensity-Modulated , Humans , Particle Accelerators , Phantoms, Imaging , Radiotherapy Dosage , Radiotherapy Planning, Computer-Assisted/methods , Radiotherapy, Intensity-Modulated/methodsABSTRACT
We previously demonstrated the simplicity of oxygen-deprived Corynebacterium glutamicum to produce D-lactate, a primary building block of next-generation biodegradable plastics, at very high optical purity by introducing heterologous D-ldhA gene from Lactobacillus delbrueckii. Here, we independently evaluated the effects of overexpressing each of genes encoding the ten glycolytic enzymes on D-lactate production in C. glutamicum. We consequently show that while the reactions catalyzed by glucokinase (GLK), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), phosphofructokinase (PFK), triosephosphate isomerase (TPI), and bisphosphate aldolase had positive effects on D-lactate productivity by increasing 98, 39, 15, 13, and 10 %, respectively, in 10 h reactions in minimal salts medium, the reaction catalyzed by pyruvate kinase had large negative effect by decreasing 70 %. The other glycolytic enzymes did not affect D-lactate productivity when each of encoding genes was overexpressed. It is noteworthy that all reactions associated with positive effects are located upstream of glycerate-1,3-bisphosphate in the glycolytic pathway. The D-lactate yield also increased by especially overexpressing TPI encoding gene up to 94.5 %. Interestingly, overexpression of PFK encoding gene reduced the yield of succinate, one of the main by-products of D-lactate production, by 52 %, whereas overexpression of GAPDH encoding gene increased succinate yield by 26 %. Overexpression of GLK encoding gene markedly increased the yield of dihydroxyacetone and glycerol by 10- and 5.8-fold in exchange with decreasing the D-lactate yield. The effect of overexpressing glycolytic genes was also evaluated in 80 h long-term reactions. The variety of effects of overexpressing each of genes encoding the ten glycolytic enzymes on D-lactate production is discussed.